PHILADELPHIA — The investigational drug verekitug improved sinonasal symptoms, reduced nasal polyp size, and reduced the need for nasal polyp surgery in people with chronic rhinosinusitis with nasal ...

Twice-yearly depemokimab is effective and well-tolerated in Chinese patients with CRwNP, according to data from the ...

Recently published Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of ...

HOUSTON -- Treatment with omalizumab (Xolair) was associated with improved endoscopic, clinical, and patient-reported outcomes in two parallel phase III studies in patients with steroid-refractory ...

Researchers discuss contributors to nasal polyp development in children, as well as the risk of co-occuring conditions and current methods of treatment. Although rarely reported in childhood, nasal ...

Please provide your email address to receive an email when new articles are posted on . Patients with nasal polyposis often experience chronic rhinosinusitis, a high symptom burden and poor quality of ...

Please provide your email address to receive an email when new articles are posted on . Extended use of omalizumab up to 1 year showed efficacy for the treatment of uncontrolled chronic rhinosinusitis ...

YARDLEY, Pa., June 2, 2021 /PRNewswire/ — Optinose (NASDAQ:OPTN), a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy ...

1 Add-on maintenance in patients with inadequate response to nasal steroids. 2 Add-on maintenance of chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with inadequate response to nasal ...

The chronic rhinosinusitis with nasal polyps market growth is being driven by rising disease prevalence, greater awareness, and improved diagnostic rates. Advancements in biologic therapies ...